Summary
Eli Lilly agreed to acquire Merida Biosciences for $2.9 billion, announced August 31, 2026. Merida’s lead drug, MER511, targets the autoantibodies that drive Graves disease. The program entered Phase 1 late last year. Consequently, Lilly has paid a multibillion-dollar price for evidence that is still years away from payer review. Therefore, the access questions deserve attention now, not at launch.
Access Impact
The deal is a bet on precision immunology. Market access will test that bet on different terms.
MER511 is designed to remove the cause of disease rather than manage its effects. Specifically, it binds to disease-causing autoantibodies and tags them for destruction. Lilly states that no current treatment for Graves disease or the related thyroid eye disease works this way. That is a strong scientific story. However, payers do not reimburse mechanisms. Instead, they reimburse demonstrated outcomes at defensible prices. Graves disease already has multiple available treatments, and MER511 will be judged against them. Lilly frames the acquisition as part of a deliberate pipeline build beyond obesity and diabetes. The article notes a series of smaller acquisitions serving that goal. Each one carries its own access case. Therefore, three MARA evidence domains will decide how this asset performs at the access gate: Clinical Effectiveness, Comparator Appropriateness, and Evidence Quality and Robustness.
Clinical Effectiveness
Human efficacy data do not yet exist. The Phase 1 study, started late last year, tests safety and dosing alongside anti-thyroid medications. As a result, every downstream assumption about effectiveness remains a projection. The claimed advantage is precise: eliminate harmful autoantibodies while preserving normal immune function. Even so, that promise must appear in outcomes payers recognize. Symptom control, relapse rates, and reduced need for further intervention are the results that will carry weight. Mechanistic elegance, by itself, carries none. Timelines compound the uncertainty. Moreover, a Phase 1 start in late 2025 places pivotal data, and any payer dialogue, years into the future.
Comparator Appropriateness
This domain will shape the entire access case. Anti-thyroid drugs are established, familiar, and inexpensive. Lilly notes that none of the current options directly target autoantibodies. Even so, HTA bodies compare results, not mechanisms. If MER511 cannot beat existing care on outcomes that matter, novelty will not rescue its price. By contrast, a clear win against standard care would give the asset a defensible position in every major market. Thyroid eye disease adds a second, related indication with its own comparator questions. The comparator strategy chosen for later trials will therefore matter as much as the molecule itself.
Evidence Quality and Robustness
Decisions made now determine defensibility later. Endpoint selection, comparator arms, and population definitions are fixed during trial design. Notably, these choices are locked in years before any payer negotiation begins. A program built only for regulatory approval often arrives at reimbursement with gaps. By contrast, a program built for both gates costs more today and far less at launch. Merida is a young company. It launched in April 2025 with a $121 million Series A round. Bain Capital Life Sciences, BVF Partners and Third Rock Ventures led that round. Consequently, the evidence architecture is still Lilly’s to define — an advantage, if used deliberately.
Risk Signal
$2.9 billion, before human proof of efficacy.
Internal deal models tend to price clinical risk with discipline and access risk with optimism. Clinical success does not equal commercial access. Moreover, the two risks compound in an asset this early. Lilly’s obesity revenue gives it room to absorb a miss. However, portfolio depth does not make any single valuation defensible. Furthermore, early-stage deals rarely document their access assumptions with the same rigor as their scientific ones. The relevant question for any board reviewing a deal like this is simple. If the access assumptions inside the valuation were challenged, which independent benchmark would support them?
#MarketAccess #HTA #MARArating #Lilly
Explore another Lilly asset independently assessed by MARA: https://mararating.com/report/foundayo-orforglipron-for-managing-overweight-and-obesity-as-of-june-2026/
Explore another Lilly asset independently assessed by MARA: https://mararating.com/report/retatrutide-for-the-treatment-of-obesity-as-of-january-2026/